Advanced
Trials portfolio
ALLCAR19
Immunotherapy for high risk/relapsed CD19+ Acute Lymphoblastic Leukaemia using CAR T-cells to target CD19
ALLCAR19 is a multi-site, non-randomised phase I trial in adults with high risk or refractory CD19+ B-cell Acute Lymphoblastic Leukaemia. The Advanced Therapy Investigational Medicinal Product (ATIMP) [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
CARD
CAR19 Donor Lymphocytes for relapsed CD19+ malignancies following allogeneic transplantation
CARD is a single centre, single arm intra-patient dose-escalation phase I study in adults with relapsed CD19+ malignancies following allogeneic stem cell transplantation. The Advanced Therapies Invest [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
CARPALL
Immunotherapy with CD19 CAR redirected T-cells for high risk/relapsed paediatric CD19+ acute lymphoblastic leukaemia and other haematological malignancies
A multi-centre, non-randomised, open label phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults with high risk, relapsed CD19+ haematolo [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
CD-19TPALL
Immunotherapy with CD19? gene modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia
a multi-site, non-randomised, phase I/II, paediatric trial with 2 arms. The Advanced Therapy Medicinal product (ATMP) tested in the study is donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) tran [...]
Area: Advanced therapies
Phase: Phase I/II
Status: Closed
COBALT
Evaluation of CAR19 T-cells as an optimal bridge to allogeneic transplantation.
Single centre, single arm dose-escalation phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults with resistant or relapsed DLBCL. The ATIMP tested in this s [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
ICAT
Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant.
ICAT is a multi-centre randomised phase II trial in adult patients with an underlying haematological malignancy undergoing unrelated donor peripheral blood stem cell transplant with Alemtuzumab-based [...]
Area: Advanced therapies
Phase: Phase II
Status: In follow-up (non-recruiting)
ITREC
Immunotherapy with Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease after Solid Organ Transplant
ITREC is a multi-site, non-randomised phase I trial in children and adults with Post Transplant Lymphoproliferative Disease (PTLD) after solid organ transplant. The Advanced Therapy Investigational Me [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
TACTICAL
Targeted stromal cells expressing TRAIL as a therapy for lung cancer
Phase I:Single site dose de-escalation design with a modified Bayesian continual reassessment method (mCRM) to estimate the recommended Phase II dose (RP2D) of MSCTRAIL in combination with pemetrexed/ [...]
Area: Advanced therapies
Phase: Phase I/II
Status: Active (recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2019 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us